2024•The medical letter on drugs and therapeutics/The medical letterRequires access

In Brief: Erzofri — Another Once-Monthly Paliperidone Formulation

Author information unavailable

Abstract

The FDA has approved Erzofri (Luye), an extended-release injectable formulation of the second-generation antipsychotic drug paliperidone palmitate, for treatment of schizophrenia and schizoaffective disorder in adults. It is the second once-monthly formulation of paliperidone palmitate to be approved in the US for these indications; Invega Sustenna was the first. Longer-acting injectable formulations of paliperidone palmitate are also available.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Paliperidone Palmitate, Paliperidone, Schizoaffective disorder, Antipsychotic drug, Schizophrenia (object-oriented programming), Extended release, Medicine, Antipsychotic